Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620653
Title:
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Authors:
Tikhonova, I. A.; Huxley, N.; Snowsill, T.; Crathorne, L.; Varley-Campbell, J. L.; Napier, Mark; Hoyle, M.
Abstract:
Combination therapies with cetuximab (Erbitux®; Merck Serono UK Ltd) and panitumumab (Vectibix®; Amgen UK Ltd) are shown to be less effective in adults with metastatic colorectal cancer who have mutations in exons 2, 3 and 4 of KRAS and NRAS oncogenes from the rat sarcoma (RAS) family.
Citation:
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. 2018 Pharmacoeconomics
Publisher:
Springer
Journal:
PharmacoEconomics
Issue Date:
1-Mar-2018
URI:
http://hdl.handle.net/11287/620653
DOI:
10.1007/s40273-018-0630-9
PubMed ID:
29498000
Additional Links:
https://dx.doi.org/10.1007/s40273-018-0630-9
Type:
Journal Article
Language:
en
ISSN:
1179-2027
Appears in Collections:
Oncology; 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorTikhonova, I. A.en
dc.contributor.authorHuxley, N.en
dc.contributor.authorSnowsill, T.en
dc.contributor.authorCrathorne, L.en
dc.contributor.authorVarley-Campbell, J. L.en
dc.contributor.authorNapier, Marken
dc.contributor.authorHoyle, M.en
dc.date.accessioned2018-03-22T11:56:43Z-
dc.date.available2018-03-22T11:56:43Z-
dc.date.issued2018-03-01-
dc.identifier.citationEconomic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. 2018 Pharmacoeconomicsen
dc.identifier.issn1179-2027-
dc.identifier.pmid29498000-
dc.identifier.doi10.1007/s40273-018-0630-9-
dc.identifier.urihttp://hdl.handle.net/11287/620653-
dc.description.abstractCombination therapies with cetuximab (Erbitux®; Merck Serono UK Ltd) and panitumumab (Vectibix®; Amgen UK Ltd) are shown to be less effective in adults with metastatic colorectal cancer who have mutations in exons 2, 3 and 4 of KRAS and NRAS oncogenes from the rat sarcoma (RAS) family.en
dc.language.isoenen
dc.publisherSpringeren
dc.relation.urlhttps://dx.doi.org/10.1007/s40273-018-0630-9en
dc.rightsArchived with thanks to PharmacoEconomicsen
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.titleEconomic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.en
dc.typeJournal Articleen
dc.identifier.journalPharmacoEconomicsen
dc.type.versionIn press (epub ahead of print)en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.